Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma.
Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio-process to purify CMRF-56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF-56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% (n = 6, purity 28%). Preparations from MM patients (n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.
Vari
F
F
Mater Medical Research Institute, The University of Queensland, Brisbane, Queensland, Australia.
Munster
D J
DJ
Hsu
J L
JL
Rossetti
T R
TR
Mahler
S M
SM
Gray
P P
PP
Turtle
C J
CJ
Prue
R L
RL
Hart
D N J
DN
D000911:Antibodies, Monoclonal / Q000302:isolation & purification; D017951:Antigen Presentation / Q000276:immunology; D000943:Antigens, Differentiation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019921:Biotinylation; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000637:transplantation*; D006801:Humans; D018189:Immunomagnetic Separation / Q000379:methods; D007937:Leukapheresis; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination / Q000379:methods
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; C119956:CMRF-56 antigen; D019496:Cancer Vaccines